Incyte leads JAK push into eczema as FDA clears Opzelura creamThe FDA has approved Incyte’s Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only Share XIncyte leads JAK push into eczema as FDA clears Opzelura creamhttps://pharmaphorum.com/news/incyte-leads-jak-push-into-eczema-as-fda-clears-opzelura-cream/
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EUIncyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative Share XIncyte, MorphoSys’ CAR-T rival tafasitamab approved in EUhttps://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/
Lilly has a bad hair day as Pfizer rival hits the mark in alopeciaEli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer Share XLilly has a bad hair day as Pfizer rival hits the mark in alopeciahttps://pharmaphorum.com/news/lilly-has-a-bad-hair-day-as-pfizer-rival-hits-the-mark-in-alopecia/
NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
Incyte preps second filing for ruxolitinib cream after vitiligo trial winIncyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can Share XIncyte preps second filing for ruxolitinib cream after vitiligo trial winhttps://pharmaphorum.com/news/incyte-preps-second-filing-for-ruxolitinib-cream-after-vitiligo-trial-win/
FDA to quickly review Incyte’s Jakafi in chronic GVHDThe FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease Share XFDA to quickly review Incyte’s Jakafi in chronic GVHDhttps://pharmaphorum.com/news/fda-to-quickly-review-incytes-jakafi-in-chronic-gvhd/
Incyte makes bid to join the checkpoint inhibitor clubIncyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal Share XIncyte makes bid to join the checkpoint inhibitor clubhttps://pharmaphorum.com/news/incyte-makes-bid-to-join-the-checkpoint-inhibitor-club/
Novartis/Incyte draw blank with Jakafi in COVID-19Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against Share XNovartis/Incyte draw blank with Jakafi in COVID-19https://pharmaphorum.com/news/novartis-incyte-draw-blank-with-jakafi-in-covid-19/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
